Time course for blood pressure lowering of dihydropyridine calcium channel blockers

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 8, 2014, Pages

  Ghamami, Niousha ^a   Chiang, Sandy Hsiang Yu ^b   Dormuth, Colin ^b   Wright, James M ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ARANIDIPINE; AZELNIDIPINE; BENIDIPINE; CILNIDIPINE; CLEVIDIPINE; DARODIPINE; DIHYDROPYRIDINE; EFONIDIPINE; ELGODIPINE; FELODIPINE; ISRADIPINE; LACIDIPINE; LERCANIDIPINE; MANIDIPINE; MEPIRODIPINE; NICARDIPINE; NIFEDIPINE; NIGULDIPINE; NILVADIPINE; NIMODIPINE; NISOLDIPINE; NITRENDIPINE; PLACEBO; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; DRUG EFFECT; HUMAN; HYPERTENSION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; ADULT; BLOOD PRESSURE; CIRCADIAN RHYTHM; DRUG ADMINISTRATION; FEMALE; MALE; META ANALYSIS; PHYSIOLOGY; TIME;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CIRCADIAN RHYTHM; DIHYDROPYRIDINES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERTENSION; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 84907169035     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010052.pub2     Document Type: Review

References (40)

1. Asmar R, Benetos A, Brahimi M, Chaouche K, Safar M. Arterial and antihypertensive effects of nitrendipine: a double-blind comparison versus placebo. Journal of Cardiovascular Pharmacology 1992;20(6):858-63. [PUBMED: 1282585]
2. Bellet M, Pagny JY, Chatellier G, Corvol P, Menard J. Evaluation of slow release nicardipine in essential hypertension by casual and ambulatory blood pressure measurements. Effects of acute versus chronic administration. Journal of Hypertension 1987;5(5):599-604. [PUBMED: 3429863]
3. Chrysant SG, Marbury TC, Robinson TD. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. Journal of Human Hypertension 2003;17(6):425-32. [PUBMED: 12764406]
4. Chrysant SG, Marbury TC, Silfani TN. Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate. Blood Press Monitoring 2006;11(3):135-41. [PUBMED: 16702822]
5. Fagan TC, Tyler ED, Reitman MA, Kenley S, Weber MA. Sustained-release nicardipine in mild-to-moderate hypertension. Chest 1993;104(2):427-33. [PUBMED: 8339631]
6. Fogari R, Zoppi A, Lusardi P, Preti P, Poletti L, Mugellini A. Evaluation by 24-hour ambulatory blood pressure monitoring of efficacy of manidipine hydrochloride 10, 20 or 40 mg once daily as compared to placebo in treating mild to moderate essential hypertension: a double-blind, randomized, parallel group, placebo-controlled study. Blood Pressure. Supplement 1996;5:16-23. [PUBMED: 8973788]
7. Fogari R, Zoppi A, Mugellini A, Preti P, Corradi L, Lusardi P. Effect of low-dose manidipine on ambulatory blood pressure in very elderly hypertensives. Cardiovascular Drugs and Therapy 1999;13(3):243-8. [PUBMED: 10439887]
8. Grimm RH Jr, Black H, Rowen R, Lewin A, Shi H, Ghadanfar M. Amlodipine versus chlorthalidone versus placebo in the treatment of stage I isolated systolic hypertension. American Journal of Hypertension 2002;15(1 Pt 1):31-6. [PUBMED: 11824857]
9. Kuschnir E, Acuna E, Sevilla D, Vasquez J, Bendersky M, Resk J, et al.Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo. Clinical Therapeutics 1996;18(6):1213-24. [PUBMED: 9001838]
10. Lacourciere Y, Lenis J, Orchard R, Lewanczuk R, Houde M, Pesant Y, et al.A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood Pressure Monitoring 1998;3(5):295-302. [PUBMED: 10212369]
11. Burris JF, Allenby KS, Mroczek WJ. The effect of amlodipine on ambulatory blood pressure in hypertensive patients. American Journal of Cardiology 1994;73(3):39A-43A. [PUBMED: 8310975]
12. Mroczek WJ, Burris JF, Allenby KS. A double-blind evaluation of the effect of amlodipine on ambulatory blood pressure in hypertensive patients. Journal of Cardiovascular Pharmacology 1988;12 Suppl 7:S79-84. [PUBMED: 2467136]
13. Mroczek WJ, Burris JF, Klein J. A double-blind evaluation of the effect of amlodipine on ambulatory blood pressure. Postgraduate Medical Journal 1991;67 Suppl 5:S24-7. [PUBMED: 1839434]
14. Omboni S, Zanchetti A. Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. Multicenter Study Investigators. Journal of Hypertension 1998;16(12 Pt 1):1831-8. [PUBMED: 9869018]
15. Pandita-Gunawardena ND, Clarke SE. Amlodipine lowers blood pressure without affecting cerebral blood flow as measured by single photon emission computed tomography in elderly hypertensive subjects. Age and Ageing 1999;28(5):451-7. [PUBMED: 10529039]
16. Toal CB. Efficacy of a low dose nifedipine GITS (20 mg) in patients with mild to moderate hypertension. Canadian Journal of Cardiology 1997;13(10):921-7. [PUBMED: 9374948]
17. van Ree JW, van der Pol GA. Low dosages of felodipine ER once daily as monotherapy in elderly hypertensive patients: effect on ambulatory blood pressure and quality of life. Journal of Human Hypertension 1996;10(9):613-8. [PUBMED: 8953207]
18. White WB, Littlejohn TW, Majul CR, Oigman W, Olvera R, Seeber M, et al.Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension. Blood Pressure Monitoring 2010;15(4):205-12. [PUBMED: 20613496]
19. Zanchetti A. The 24-hour efficacy of a new once-daily formulation of nifedipine. Italian Nifedipine GITS Study Group. Drugs 1994;48 Suppl 1:23-30; discussion 30-1. [PUBMED: 7533703]
20. Zanchetti A. Trough and peak effects of a single daily dose of nifedipine gastrointestinal therapeutic system (GITS) as assessed by ambulatory blood pressure monitoring. Italian Nifedipine GITS Study Group. Journal of Hypertension Supplement 1994;12(5):S23-7. [PUBMED: 7965282]
21. Zanchetti A, Bianchi L, Amigoni S, Omboni S, Villani A, Ravogli A. Antihypertensive effects of nifedipine gastrointestinal therapeutic system on clinic and ambulatory blood pressure in essential hypertensives. Italian GITS Study Group. Journal of Hypertension Supplement 1993;11(5):S334-5. [PUBMED: 8158410]
22. Carr AA, Bottini PB, Feig P, Prisant LM, Mulligan S, Devane JG, et al.Effectiveness of once-daily monotherapy with a new nifedipine sustained release calcium antagonist. American Journal of Cardiology 1992;69(13):28E-32E. [PUBMED: 1575174]
23. Honorato J, Azanza J, Guindo N, Suarez JR. Double-blind placebo-controlled study of the antihypertensive efficacy of nitrendipine in patients submitted to ambulatory blood pressure monitoring. Current Therapeutic Research, Clinical and Experimental 1989;46(5):932-9.
24. Viskoper JR, Laszt A, Farragi D. The antihypertensive action of isradipine in mild essential hypertension. Journal of Cardiovascular Pharmacology 1991;18 Suppl 3:S9-11. [PUBMED: 1720488]
25. Zachariah PK, Schwartz GL, Sheps SG, Schirger A, Carlson CA, Moore AG. Antihypertensive effects of a new sustained-release formulation of nifedipine. Journal of Clinical Pharmacology 1990;30(11):1012-9. [PUBMED: 2243148]
26. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
27. Basile J. The role of existing and newer calcium channel blockers in the treatment of hypertension. Journal of Clinical Hypertension (Greenwich) 2004;6(11):621-9.
28. Chen N, Zhou M, Yang M, Guo J, Zhu C, Yang J, et al.Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Database of Systematic Reviews 2010, Issue 8. [DOI: 10.1002/14651858.CD003654]
29. Elliott WJ. Circadian variation in blood pressure: implications for the elderly patient. American Journal of Hypertension 1999;12(2 Pt 2):43S-9S. [PUBMED: 10090294]
30. Elliott WJ, Ram CV. Calcium channel blockers. Journal of Clinical Hypertension (Greenwich) 2011;13(9):687-9.
31. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
32. Kario K, Shimada K. Risers and extreme-dippers of nocturnal blood pressure in hypertension: antihypertensive strategy for nocturnal blood pressure. Clinical and Experimental Hypertension 2004;26(2):177-89. [PUBMED: 15038628]
33. Perez MI, Linden W, Perry T Jr, Puil LJ, Wright JM. Failure of psychological interventions to lower blood pressure: a randomized controlled trial. Open Medicine 2009;3(2):e92-e100. [PUBMED: 19946397]
34. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, et al.Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003;289:2534-44.
35. Sekhon R, Perez MI, Wright JM. Time course for blood pressure lowering of thiazides. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD007436]
36. Sica DA. Pharmacotherapy review: calcium channel blockers. Journal of Clinical Hypertension (Greenwich) 2006;8(1):53-6. [PUBMED: 16407690]
37. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
38. Toyo-Oka T, Nayler WG. Third generation calcium entry blockers. Blood Pressure 1996;5(4):206-8. [PUBMED: 8809370]
39. Turnbull F, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362(9359):1527-35.
40. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD001841]